| Hazard Information | Back Directory | [Description]
CS1 is a potent inhibitor of microtubule polymerization via interaction with the colchicine-binding pocket of tubulin, inducing unique histone phosphorylation patterns distinct from those induced by colchicine. CS1 is an antimitotic. | [Uses]
CS1 is a potent DNA Topo II α inhibitor. CS1 displays broad-spectrum in vitro antitumor effects, low toxicity in vivo and potential anti-multidrug resistance capabilities. CS1 leads to DNA damage, cell cycle arrest at G2/M phase and apoptosis[1]. | [in vivo]
CS1 (20 mg/kg; i.v.; every other day for two weeks) shows antitumor effects[1]. | Animal Model: | Five-week-old female athymic nude mice (BALB/c-nu)[1] | | Dosage: | 20 mg/kg | | Administration: | i.v., every other day for two weeks | | Result: | Showed antitumor effects. |
| [IC 50]
topoisomerase II alpha | [References]
[1] Shen Y, et al. CS1 is a novel topoisomerase IIα inhibitor with favorable drug resistance profiles. Biochem Biophys Res Commun. 2014; 453(3):302-8. DOI:10.1016/j.bbrc.2014.09.042 |
|
| Company Name: |
Energy Chemical
|
| Telephone: |
400-0056266 |
| Website: |
www.energy-chemical.com |
|